<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568395</url>
  </required_header>
  <id_info>
    <org_study_id>20-001179</org_study_id>
    <nct_id>NCT04568395</nct_id>
  </id_info>
  <brief_title>Acute Effects of TCIG vs ECIG in PLWH</brief_title>
  <official_title>Acute Impact of Switching From Tobacco Cigarettes to E-Cigarettes in People Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tobacco Related Disease Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled trial of acute use of electronic cigarette or tobacco cigarette on&#xD;
      parameters of ventricular repolarization and inflammation/oxidative stress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On separate days, participants will undergo 3 different exposures: an acute e-cigarette&#xD;
      exposure, an acute tobacco cigarette exposure, and a sham (empty e-cigarette) control .&#xD;
      Before and after the acute exposure, participants will have blood drawn for&#xD;
      inflammation/oxidative stress markers and undergo a 5-minute ECG recording.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Crossover with 1 week washout</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>single (outcomes assessor) code</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tpe</measure>
    <time_frame>Change in Tpe 5 minutes after cigarette use</time_frame>
    <description>interval indicative of ventricular repolarization measured on ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tpe/QT</measure>
    <time_frame>Change in Tpe/QT after cigarette use</time_frame>
    <description>interval indicative of ventricular repolarization measured on ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tpe/QTc</measure>
    <time_frame>Change in Tpe/QTc after cigarette use</time_frame>
    <description>interval indicative of ventricular repolarization measured on ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cellular Reactive Oxygen Stress</measure>
    <time_frame>within 4 hours of cigarette use</time_frame>
    <description>total cellular oxidative stress measured by flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QT</measure>
    <time_frame>Change in QT after cigarette use</time_frame>
    <description>interval indicative of ventricular repolarization measured on ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc</measure>
    <time_frame>Change in QTc after cigarette use</time_frame>
    <description>interval indicative of ventricular repolarization measured on ECG</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>E Cigarette Use</condition>
  <condition>Vaping</condition>
  <condition>Smoking</condition>
  <condition>Tobacco Smoking</condition>
  <condition>Nicotine Use Disorder</condition>
  <condition>Qt Interval, Variation in</condition>
  <condition>HIV I Infection</condition>
  <condition>Oxidative Stress</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>PLWH smoker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLWH who smoke will undergo 3 interventions : acute TCIG use, acute ECIG use and acute sham control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TCIG</intervention_name>
    <description>Use a TCIG</description>
    <arm_group_label>PLWH smoker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ECIG</intervention_name>
    <description>Use an ECIG</description>
    <arm_group_label>PLWH smoker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham control</intervention_name>
    <description>Use a sham control (empty ECIG)</description>
    <arm_group_label>PLWH smoker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Chronic (&gt; 1year) TCIG smoker HIV positive Stable ART Viral count non-detectable CD4 &gt;500&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Known major illness (heart disease, diabetes, lung or liver disease) Daily recreational&#xD;
        drug use, including cannabis &gt;2 alcoholic drinks per day Obesity (&gt;30 kg/m2) Recent (&lt;3&#xD;
        months) infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Holly Middlekauff, MD</last_name>
    <phone>310-206-6672</phone>
    <email>hmiddlekauff@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Ruedisueli, BS</last_name>
    <phone>310-825-3510</phone>
    <email>iruedisueli@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>890095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izzy Ruedisueli, BS</last_name>
      <phone>310-825-3510</phone>
      <email>iruedisueli@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Holly Middlekauff, MD</last_name>
      <phone>310-206-6672</phone>
      <email>hmiddlekauff@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCaliforniaLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly R Middlekauff, MD</last_name>
      <phone>310-206-6672</phone>
      <email>hmiddlekauff@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle Ruedisueli, BS</last_name>
      <phone>310-825-3510</phone>
      <email>iruedisueli@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Holly R Middlekauff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Holly R Middlekauff</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

